/CHGCF

CHGCF Stock - Chugai Pharmaceutical Co., Ltd.

Q: What is the analyst price target for CHGCF?

Analyst price target information is not currently available for CHGCF.

Q: What is CHGCF's market cap?

Market capitalization information is not currently available for CHGCF.

Healthcare|Drug Manufacturers - General|OTC

$52.65-0.09%

$0.05 (-0.09%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $57.92

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for CHGCF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.39

52W High$72.30

52W Low$32.25

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$1.17T	$1.11T	$1.26T	$999.76B	$786.95B
Gross Profit	$831.20B	$698.06B	$783.70B	$661.61B	$513.48B
Gross Margin	71.0%	62.8%	62.2%	66.2%	65.2%
Operating Income	$542.00B	$439.17B	$533.31B	$421.90B	$301.23B
Net Income	$387.32B	$325.47B	$374.43B	$303.00B	$214.73B
Net Margin	33.1%	29.3%	29.7%	30.3%	27.3%
EPS	$235.35	$197.80	$227.64	$184.29	$130.66

Company Overview

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; osteoporosis, including Actemra, Edirol, and Bonviva; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Visit Website

Earnings History & Surprises

CHGCF

Beat Rate

59%

Last 17 quarters

Avg Surprise

+885.2%

EPS vs Estimate

Beats / Misses

10/6

1 met exactly

Latest EPS

$0.00

Q4 2025

EPS Surprise History

Q1 24

+15.2%

$0.38vs$0.33

Q2 24

+5.4%

$0.29vs$0.27

Q3 24

+30.2%

$0.44vs$0.34

Q4 24

-2.9%

$0.44vs$0.45

Q1 25

+14933.5%

$0.36vs$0.00

Q2 25

+21.7%

$0.41vs$0.34

Q3 25

-20.7%

$0.41vs$0.51

Q4 25

-99.4%

$0.00vs$0.50

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	Apr 22, 2026	—	—	—	—
Q1 2026	Jan 29, 2026	—	—	—	—
Q4 2025	Oct 24, 2025	$0.50	$0.00	-99.4%	✗ MISS
Q3 2025	Jul 24, 2025	$0.51	$0.41	-20.7%	✗ MISS
Q2 2025	Apr 24, 2025	$0.34	$0.41	+21.7%	✓ BEAT
Q1 2025	Jan 30, 2025	$0.00	$0.36	+14933.5%	✓ BEAT
Q4 2024	Oct 25, 2024	$0.45	$0.44	-2.9%	✗ MISS
Q3 2024	Jul 25, 2024	$0.34	$0.44	+30.2%	✓ BEAT
Q2 2024	Apr 24, 2024	$0.27	$0.29	+5.4%	✓ BEAT
Q1 2024	Feb 1, 2024	$0.33	$0.38	+15.2%	✓ BEAT
Q4 2023	Oct 24, 2023	$0.35	$0.31	-11.2%	✗ MISS
Q3 2023	Jul 27, 2023	$0.33	$0.36	+10.2%	✓ BEAT
Q2 2023	Apr 27, 2023	$0.33	$0.33	-0.3%	✗ MISS
Q1 2023	Feb 2, 2023	$0.45	$0.48	+6.8%	✓ BEAT
Q4 2022	Oct 24, 2022	$0.31	$0.28	-8.4%	✗ MISS
Q3 2022	Jul 21, 2022	$0.32	$0.32	0.0%	= MET
Q2 2022	Apr 25, 2022	$0.28	$0.62	+122.5%	✓ BEAT
Q1 2022	Feb 3, 2022	$0.47	$0.52	+10.2%	✓ BEAT
Q4 2021	Oct 22, 2021	$0.34	$0.46	+35.6%	✓ BEAT
Q3 2021	Jul 26, 2021	—	$0.39	—	—

Frequently Asked Questions about CHGCF

What is CHGCF's current stock price?

Chugai Pharmaceutical Co., Ltd. (CHGCF) is currently trading at $52.65 per share. The stock has moved -0.09% today.

What is the analyst price target for CHGCF?

No analyst price targets are currently available for this stock.

What sector is Chugai Pharmaceutical Co., Ltd. in?

Chugai Pharmaceutical Co., Ltd. operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the OTC exchange.

What is CHGCF's market cap?

Chugai Pharmaceutical Co., Ltd. has a market capitalization of $86.65 billion, making it a large-cap company.

Does CHGCF pay dividends?

No, Chugai Pharmaceutical Co., Ltd. does not currently pay a dividend to shareholders.